Literature DB >> 14635183

In vivo imaging and tumor therapy with the sodium iodide symporter.

David Dingli1, Stephen J Russell, John C Morris.   

Abstract

There has been great progress in the design of vectors for cancer gene therapy. However, it has been difficult to translate success in the laboratory into clinical practice. A major hurdle in understanding these failures has been the relative difficulty in monitoring repeatedly and non-invasively the biodistribution, gene expression and replication of these viral vector systems. With the advent of molecular imaging technology, this deficiency is being rapidly rectified. A number of reporter genes have been used to monitor gene expression. In this review, we discuss the role of the sodium iodide symporter (NIS) as a reporter and therapeutic gene for cancer gene therapy when combined with various radioactive isotopes. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635183     DOI: 10.1002/jcb.10714

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  36 in total

1.  Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor.

Authors:  David Dingli; Brad J Kemp; Michael K O'Connor; John C Morris; Stephen J Russell; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

Review 2.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 3.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

4.  In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Authors:  Mi-Yeon Jung; Chetan P Offord; Matthew K Ennis; Iris Kemler; Claudia Neuhauser; David Dingli
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

5.  Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.

Authors:  Kathrin Klutz; Michael J Willhauck; Nathalie Wunderlich; Christian Zach; Martina Anton; Reingard Senekowitsch-Schmidtke; Burkhard Göke; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

Review 6.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

7.  Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.

Authors:  Lauro Velazquez-Salinas; Shruthi Naik; Steven J Pauszek; Kah-Whye Peng; Stephen J Russell; Luis L Rodriguez
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

8.  Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Ileana Aderca; Mark J Federspiel; Donald J Tindall; John C Morris; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

Review 9.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

10.  Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.

Authors:  Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; David Dingli; Claire E Bender; Bradley J Kemp; Stephen J Russell
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.